Neurocrine Biosciences (NASDAQ:NBIX) Insider Darin Lippoldt Sells 9,800 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 9,800 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $170.16, for a total value of $1,667,568.00. Following the completion of the sale, the insider directly owned 54,729 shares of the company’s stock, valued at approximately $9,312,686.64. This trade represents a 15.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt also recently made the following trade(s):

• On Friday, June 26th, Darin Lippoldt sold 200 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $169.56, for a total value of $33,912.00.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded down $1.46 during mid-day trading on Tuesday, hitting $168.54. The company’s stock had a trading volume of 1,074,857 shares, compared to its average volume of 1,187,589. The firm’s 50 day moving average is $152.82 and its 200 day moving average is $141.25. The company has a market cap of $16.95 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 0.67 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $171.50.

Analyst Ratings Changes

A number of research firms have recently issued reports on NBIX. Truist Financial increased their price target on shares of Neurocrine Biosciences from $140.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Citigroup boosted their price objective on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $185.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 6th. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price for the company. Finally, Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $187.52.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. USA Financial Formulas acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth $25,000. Geneos Wealth Management Inc. raised its holdings in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. DJE Kapital AG acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at $28,000. Basecamp Wealth Advisors LLC lifted its stake in shares of Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new stake in Neurocrine Biosciences in the first quarter worth $33,000. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.